JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy

Selective Janus kinase inhibitors come of age

(2019) John J. O’Shea et al.   Nature Reviews Rheumatology

Janus kinases to jakinibs: from basic insights to clinical practice

(2019) Massimo Gadina et al.   RHEUMATOLOGY

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Gerd R Burmester et al.   LANCET

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review

(2018) Paul Emery et al.   ADVANCES IN THERAPY

Methotrexate mechanism in treatment of rheumatoid arthritis

(2018) Benjamin Friedman et al.   JOINT BONE SPINE

STAT signaling as a marker of SLE disease severity and implications for clinical therapy

(2018) Aleš Goropevšek et al.   AUTOIMMUNITY REVIEWS

Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials

(2018) Simon Tarp et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Low-dose methotrexate in myeloproliferative neoplasm models

(2017) Kavitha Chinnaiya et al.   HAEMATOLOGICA

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials

(2017) Simon Tarp et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Low-dose methotrexate in myeloproliferative neoplasm models

(2017) Kavitha Chinnaiya et al.   HAEMATOLOGICA

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity

(2016) Francesca Palandri et al.   AMERICAN JOURNAL OF HEMATOLOGY

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

(2016) R Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial

(2016) Johannes W J Bijlsma et al.   LANCET

Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression

(2016) Yuan-bo Li et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010

(2015) Ayako Nakajima et al.   Modern Rheumatology

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs

(2015) Dimitrios A. Pappas et al.   ARTHRITIS CARE & RESEARCH

Methotrexate Is a JAK/STAT Pathway Inhibitor

(2015) Sally Thomas et al.   PLoS One

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

(2014) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes

(2014) Charles F. Spurlock et al.   RHEUMATOLOGY

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

(2014) Glynn Dennis et al.   ARTHRITIS RESEARCH & THERAPY

Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages

(2013) Balázs Koscsó et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein

(2013) Yuki Kuroiwa et al.   PLoS One

Regulation of Inflammation by Adenosine

(2013) György Haskó et al.   Frontiers in Immunology

Regulation of Macrophage Function by Adenosine

(2012) György Haskó et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Protein Kinase Signaling Systems Regulating Lifespan Identified by Small Molecule Library Screening Using Drosophila

(2012) Stephen R. Spindler et al.   PLoS One

Interleukin-6 regulates anti-arthritic effect of methotrexate via reduction of SLC19A1 expression in a mouse arthritis model

(2012) Misato Hashizume et al.   ARTHRITIS RESEARCH & THERAPY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS